do glp 1 cause heart problems Cardiovascular effects of Glucagon-like peptide (GLP-1) receptor agonists | Cardiovascular Diabetology Frontiers | The potential of
Description
Pfizer is developing a long-acting GLP-1 drug that could compete directly with Eli Lilly's Mounjaro and Zepbound when it reaches the Canadian market.
It is a newer drug on the market, and there is still some research being done on it, but the results so far have been very promising
Methods Blood was drawn from 24 subjects (14 male, 10 female, age: 50.77.36years, BMI: 26.643.38kg/m2, GHbA1c: 7.000.74%) with drug-nave T2D at 0 and 120min following a standard mixed meal for the measurements of active GLP-1, NO and NOS
Discover whether tirzepatide is linked to numbness or tingling, explore alternative causes including diabetic neuropathy, and learn when to seek medical advice for neurological symptoms during treatment.
But what do we need to consider when using them in older age
